By Marine De Lageneste, Yan Haibo, Calley Hirsch, Candace Rhodes, and Aaron Dulgar-Tulloch
Clinical and biopharmaceutical communities are undergoing an evolution in cancer treatment with the development and use of T cell immunotherapies. The approval of autologous CAR T cell therapies from Novartis (Kymriah™) and Gilead/Kite (Yescarta™) emphasizes the growing need for automated and closed solutions to industrialize cell and gene therapy manufacturing with enhanced risk management, scalability, and reproducibility. Although equipment is available for most workflow steps of CAR T cell therapy manufacturing, other steps, such as lentiviral transduction for gene transfer, need improved methods and technologies.
SpinOculation C-Pro protocol software, used in combination with Sepax™ C-Pro instrument and single-use disposable kit CT-60.1, is a new stand-alone solution developed to streamline and automate lentiviral transduction while maintaining flexibility during process development. This application allows users to adjust the input cell volume to reach a specific cell density during the transduction step. Also, it provides closed system centrifugation to aid in gene transfer without the use of enhancers. The final output volume is adaptable to the customer-specific application. Here, we present two user cases as examples of using SpinOculation C-Pro protocol software for lentiviral vector transduction in different CAR T cell workflows .